TCT 2019 | TWILIGHT: Minimal DAPT in High Bleeding Risk Patients

Courtesy of the SBHCI.

Monotherapy with a P2Y12 inhibitor after a minimum period (3 months) of dual antiplatelet antiaggregation (DAPT) is a valid treatment option to reduce bleeding in patients at high risk of bleeding complications. 

Highlights TCT 2019

The present double-blind study presented at TCT 2019 simultaneously published in NEJM analyzed ticagrelor monotherapy (prior 3 months DAPT) vs DAPT in patients undergoing PCI at high risk of bleeding. 

After 3 months of ticagrelor + aspirin, patients free from ischemic or bleeding events were randomized to ticagrelor + placebo (ticagrelor monotherapy) vs. ticagrelor + aspirin (DAPT) up to 12 months. 

Of 9006 included patients, 7119 were finally randomized (the rest were excluded for presenting bleeding or ischemic events).


Read also: TCT 2019 | Onyx ONE: Durable Polymer vs. Polymer-Free Stent with Only One Month of Dual Antiplatelet Therapy.


Primary end point was BARC bleeding 2, 3 or 5.

At one year, primary end point was seen in 4% of patients randomized to ticagrelor + placebo vs. 7.1% in patients with ticagrelor + aspirin (p<0.001).

The difference was driven mainly by BARC 2 bleeding, since major bleeding (BARC 3 or 5) resulted similar, as was all cause death, non-fatal stroke and non-fatal infarction. 

Conclusion

PCI Patients at high risk of bleeding after 3 months DAPT can continue with ticagrelor monotherapy up to 12 months, reducing bleeding events with no risk of increasing ischemic events, compared against ticagrelor + aspirin. 

Courtesy of the SBHCI.

Link to the SBHCI publication HERE

twilight-slides

nejm-twilight

Original Title: TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI.

Author of the Original Article: Roxana Mehran.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....